SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BiondVax Pharmaceuticals Ltd. (BVXV) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 38/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BVXV
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-24.59 |
$0.00 |
$-8.04M |
- |
| 2014 |
$-23.76 |
$0.00 |
$-7.76M |
- |
| 2015 |
$-38.66 |
$0.00 |
$-10.2M |
- |
| 2016 |
$-27.19 |
$0.00 |
$-9.18M |
- |
| 2017 |
$-68.75 |
$0.00 |
$-34.55M |
- |
| 2018 |
$-35.64 |
$0.00 |
$-23.29M |
- |
| 2019 |
$-151.98 |
$0.00 |
$-124.11M |
- |
| 2020 |
$6.15 |
$0.00 |
$6.82M |
- |
| 2021 |
$-36.00 |
$0.00 |
$-50.81M |
- |
| 2022 |
$0.00 |
$0.00 |
$-531K |
- |
